• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    2/13/24 4:59:02 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    SC 13G/A 1 tv0323-arcturustherapeuticsh.htm SCHEDULE 13G/A arcturustherapeuticsholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Arcturus Therapeutics Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  03969T109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  03969T109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    18,233

    7.  SOLE DISPOSITIVE POWER

    1,419,029

    8.  SHARED DISPOSITIVE POWER

    39,351

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,458,380

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.46%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Arcturus Therapeutics Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10628 Science Center Drive, Suite 250
    San Diego, CA 92121

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    03969T109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ARCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    5/28/2025$32.00Sector Outperform
    Scotiabank
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    More analyst ratings

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Arcturus Therapeutics with a new price target

    Scotiabank initiated coverage of Arcturus Therapeutics with a rating of Sector Outperform and set a new price target of $32.00

    5/28/25 8:57:14 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Arcturus Therapeutics with a new price target

    BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00

    1/28/25 8:51:42 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Arcturus Therapeutics with a new price target

    Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00

    8/12/24 7:16:41 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sassine Andy bought $20,499 worth of shares (1,238 units at $16.56), increasing direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/20/25 4:01:44 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sassine Andy decreased direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/19/25 4:05:30 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Farrell Peter C

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    6/11/25 8:02:07 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    SEC Filings

    View All

    SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

    10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

    8/11/25 4:14:38 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

    8/11/25 4:01:46 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    7/30/25 1:16:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

    Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod

    8/11/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link Abou

    7/24/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Attend Upcoming Investor Conferences

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: BTIG Virtual Biotechnology Conference 2025 (Fireside Chat) Tuesday, July 29, 2025 (12:40 p.m. ET) CG 45th Annual Growth Conference (Presentation) Tuesday, August 12, 2025 (8:30 a.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines com

    7/23/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sassine Andy bought $20,499 worth of shares (1,238 units at $16.56), increasing direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/20/25 4:01:44 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sassine Andy decreased direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/19/25 4:05:30 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Financials

    Live finance-specific insights

    View All

    Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

    Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod

    8/11/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link Abou

    7/24/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

    Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight

    5/12/25 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/8/24 3:17:24 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/5/24 6:07:26 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    4/5/24 12:18:33 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

    2/4/25 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

    Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

    6/20/24 8:00:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Appoints John Markels, Ph.D. to its Board of Directors

    Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

    12/13/22 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care